All In Biotech

Drug Trial Radar · NCT04533529

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy and an Open-labeled Long-term Safety Extension Treatment With Seltorexant

Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 588 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

588

Actual

Start

Sep 16, 2020

Primary completion

Apr 25, 2023

Study completion Apr 30, 2024

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Aug 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with an selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) in double-blind treatment phase and to assess the long-term safety and tolerability of seltorexant as adjunctive therapy to an antidepressant in participants with major depressive disorder (MDD) in open-label treatment phase.

Conditions

  • Depressive Disorder, Major

Interventions

  • SeltorexantDrug

    Seltorexant tablet will be administered orally once daily.

  • PlaceboDrug

    Matching placebo tablet will be administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1Time frame: Baseline (Day 1), Day 43
  2. Open Label (OL) Treatment Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)
  3. OL Treatment Phase: Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)Time frame: From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)
  4. OL Treatment Phase: Change From Baseline in Vital Signs: Blood PressureTime frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
  5. OL Treatment Phase: Change From Baseline: Body Mass Index (BMI)Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
  6. OL Treatment Phase: Change From Baseline in Vital Signs: TemperatureTime frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
  7. OL Treatment Phase: Change From Baseline in Vital Signs: Pulse RateTime frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
  8. OL Treatment Phase: Change From Baseline in WeightTime frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
  9. OL Treatment Phase: Change From Baseline in Waist CircumferenceTime frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
  10. OL Treatment Phase: Number of Participants With Shift From Baseline in Suicidal Ideation and Behavior Using the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: From DB Baseline (Day 1) up to Week 52
  11. OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Start of OL Follow UpTime frame: Start of OL Follow Up (Week 52)
  12. OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 1Time frame: Follow up Visit 1: 1 day after end of OL phase (Week 52.14)
  13. OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 2Time frame: Follow Up Visit 2: 2 weeks after end of OL phase (Week 54)
  14. OL Treatment Phase: Number of Participants With Electrocardiogram (ECG) AbnormalitiesTime frame: Week 52
  15. OL Treatment Phase: Number of Participants With Clinically Significant Laboratory AbnormalitiesTime frame: From DB Baseline (Day 1) to Week 52
  16. OL Treatment Phase: Number of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) ScoreTime frame: Week 52

Locations

122 sites in 11 countries. Site status is shown where the registry gives one.

  • Advanced Research Center Inc

    Anaheim, California

  • Synexus

    Cerritos, California

  • Irvine Clinical Research

    Irvine, California

  • Omega Clinical Trials LLC

    La Habra, California

  • Synergy East

    Lemon Grove, California

  • Semel Institute for Neuroscience and Human Behavior

    Los Angeles, California

  • Catalina Research Institute

    Montclair, California

  • Pacific Research Partners

    Oakland, California

  • North County Clinical Research

    Oceanside, California

  • Syrentis Clinical Research

    Santa Ana, California

  • Viking Pharmaceutical Trials Inc. dba Viking Clinical Research

    Temecula, California

  • Connecticut Clinical Trials LLC

    Cromwell, Connecticut

  • University of Connecticut Health Center

    Farmington, Connecticut

  • Sarkis Clinical Trials

    Gainesville, Florida

  • Clinical NeuroScience Solutions Inc

    Jacksonville, Florida

  • Pharmax Research Clinic Inc

    Miami, Florida

  • Medical Research Center of Miami II Inc

    Miami, Florida

  • Phoenix Medical Research, Inc.

    Miami, Florida

  • Galiz Research

    Miami Springs, Florida

  • Bravo Health Care Center

    North Bay Village, Florida

  • APG Research LLC

    Orlando, Florida

  • Combined Research Orlando

    Orlando, Florida

  • Nova Psychiatry INC

    Orlando, Florida

  • Revive Research Institute

    Elgin, Illinois

  • Joliet Center for Clinical Research

    Joliet, Illinois

  • Baber Research Group

    Naperville, Illinois

  • American Medical Research, Inc.

    Oak Brook, Illinois

  • Southern Illinois University School of Medicine

    Springfield, Illinois

  • Louisiana Clinical Research

    Shreveport, Louisiana

  • Adams Clinical

    Watertown, Massachusetts

  • Neurobehavioral Medicine Group

    Bloomfield Hills, Michigan

  • Midwest Research Group - St. Charles Psychiatric Associates

    Saint Charles, Missouri

  • Mid-America Clinical Research, LLC

    St Louis, Missouri

  • PsychCare Consultants Research

    St Louis, Missouri

  • Premier Psychiatric Research Institute, LLC

    Lincoln, Nebraska

  • Altea Research Institute

    Las Vegas, Nevada

  • Hassman Research Institute, LLC.

    Berlin, New Jersey

  • Synexus Clinical Research US Inc

    Jamaica, New York

  • Bioscience Research LLC

    Mount Kisco, New York

  • Haidar Almhana Nieding

    Avon Lake, Ohio

Showing 40 of 122 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.